SRRK icon

Scholar Rock

37.83 USD
+0.56
1.50%
At close Jul 30, 4:00 PM EDT
After hours
38.05
+0.22
0.58%
1 day
1.50%
5 days
-4.30%
1 month
6.80%
3 months
14.95%
6 months
-6.36%
Year to date
-14.33%
1 year
312.09%
5 years
232.72%
10 years
144.06%
 

About: Scholar Rock Holding Corp is a late-stage biopharmaceutical company focused on discovering, developing, and delivering innovative medicines for treating serious diseases in which signaling by protein growth factors plays a fundamental role. Its pipeline includes Neuromuscular and Obesity, Immuno-oncology, Fibrotic Disease, and Hematology. The group operates and manages its business as a single segment to assess performance and make operating decisions.

Employees: 196

0
Funds holding %
of 7,323 funds
Analysts bullish %

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

44% more call options, than puts

Call options by funds: $22.8M | Put options by funds: $15.9M

28% more repeat investments, than reductions

Existing positions increased: 88 | Existing positions reduced: 69

26% more first-time investments, than exits

New positions opened: 39 | Existing positions closed: 31

3% more funds holding

Funds holding: 224 [Q4 2024] → 230 (+6) [Q1 2025]

0.74% less ownership

Funds ownership: 111.47% [Q4 2024] → 110.73% (-0.74%) [Q1 2025]

11% less funds holding in top 10

Funds holding in top 10: 9 [Q4 2024] → 8 (-1) [Q1 2025]

25% less capital invested

Capital invested by funds: $4.51B [Q4 2024] → $3.37B (-$1.14B) [Q1 2025]

Research analyst outlook

We haven’t received any recent analyst ratings for SRRK.

Financial journalist opinion

Based on 3 articles about SRRK published over the past 30 days

Positive
The Motley Fool
1 week ago
Director Sells 11,136 Shares of SRRK, a Stock Up 330% in Past Year
On July 18, 2025, Director Jeffrey S. Flier disclosed the sale of 11,136 shares of Scholar Rock (SRRK -0.68%) in an open market transaction.
Director Sells 11,136 Shares of SRRK, a Stock Up 330% in Past Year
Neutral
Business Wire
1 week ago
Scholar Rock to Host Conference Call to Discuss Second Quarter 2025 Financial Results and Provide Business Update on August 6, 2025
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on developing and commercializing apitegromab for patients with spinal muscular atrophy (SMA) and other severe and debilitating neuromuscular diseases, today announced that management will host a conference call to discuss its second quarter 2025 financial results and provide a business update on Wednesday, August 6, 2025, at 8:00am ET. To access the live conference call, participants.
Scholar Rock to Host Conference Call to Discuss Second Quarter 2025 Financial Results and Provide Business Update on August 6, 2025
Neutral
Business Wire
1 week ago
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK; the “Company”), a late-stage biopharmaceutical company focused on developing and commercializing apitegromab for patients with spinal muscular atrophy (SMA) and other severe and debilitating neuromuscular diseases, today announced that the company granted inducement equity awards covering an aggregate of 224,100 shares of its common stock to 6 newly hired employees, consisting of inducement stock options to purchase an aggregate of.
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Positive
CNBC Television
1 month ago
Scholar Rock CEO on its drug that could preserve muscle in weight-loss drug users
David Hallal, Scholar Rock CEO, joins 'Fast Money' to talk its recent drug study results that found its drug taken in combination with Zepbound helped prevent muscle loss.
Scholar Rock CEO on its drug that could preserve muscle in weight-loss drug users
Neutral
Business Wire
1 month ago
Scholar Rock to Present Comprehensive Update at 2025 Annual Cure SMA Research and Clinical Care Meeting, Including Positive Results from Pivotal Phase 3 SAPPHIRE Trial
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on developing and commercializing apitegromab for patients with spinal muscular atrophy (SMA) and other severe and debilitating neuromuscular diseases, announced today that it will present data from its Phase 3 SAPPHIRE clinical trial (NCT05156320) in an oral presentation at Cure SMA's Annual SMA Research & Clinical Care Meeting being held June 25-27, 2025, in Anaheim, California.
Scholar Rock to Present Comprehensive Update at 2025 Annual Cure SMA Research and Clinical Care Meeting, Including Positive Results from Pivotal Phase 3 SAPPHIRE Trial
Positive
The Motley Fool
1 month ago
Why Scholar Rock Shares Are Soaring Today
Shares of Scholar Rock Holding (SRRK 14.93%) are soaring today, up 13.7% as of 1:14 p.m. ET. The move comes as the S&P 500 and Nasdaq Composite were up modestly.
Why Scholar Rock Shares Are Soaring Today
Positive
Benzinga
1 month ago
Scholar Rock's Atrophy Drug When Combined With Eli Lilly's Zepbound Shows Around 55% Better Muscle Preservation In Weight Loss Study
Scholar Rock  SRRK revealed results on Wednesday from the Phase 2 EMBRAZE proof-of-concept trial assessing apitegromab in combination with tirzepatide to preserve lean mass during tirzepatide-induced weight loss.
Scholar Rock's Atrophy Drug When Combined With Eli Lilly's Zepbound Shows Around 55% Better Muscle Preservation In Weight Loss Study
Positive
Market Watch
1 month ago
Scholar Rock Shares Jump on Positive Results from Weight Loss Trial
Shares of Scholar Rock climbed after the company disclosed what it called positive results from a Phase 2 study assessing its drug for weight loss.
Scholar Rock Shares Jump on Positive Results from Weight Loss Trial
Positive
Reuters
1 month ago
Scholar Rock's drug helps preserve lean mass in mid-stage trial
Scholar Rock said on Wednesday its experimental drug helped overweight patients preserve lean mass in a mid-stage trial when used in combination with Eli Lilly's weight-loss treatment.
Scholar Rock's drug helps preserve lean mass in mid-stage trial
Neutral
Business Wire
1 month ago
Scholar Rock Reports Positive Phase 2 EMBRAZE Trial Results Demonstrating Statistically Significant Preservation of Lean Mass with Apitegromab During Tirzepatide-Induced Weight Loss
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on developing and commercializing apitegromab for patients with spinal muscular atrophy (SMA) and additional severe and debilitating neuromuscular diseases, today announced positive results from the Phase 2 EMBRAZE proof-of-concept trial assessing apitegromab in combination with tirzepatide to preserve lean mass during tirzepatide-induced weight loss. The trial demonstrated that 30% of.
Scholar Rock Reports Positive Phase 2 EMBRAZE Trial Results Demonstrating Statistically Significant Preservation of Lean Mass with Apitegromab During Tirzepatide-Induced Weight Loss
Charts implemented using Lightweight Charts™